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Summary
 Aim To evaluate the treatment results of squamous cell carcinoma of the oral cavity 
treated with radical or postoperative radiotherapy at the Institute of Oncology 
Ljubljana, in the period 1990–1995.
 Materials/Methods The medical records of patients were used to collect the data according to the 
predeﬁ ned Data Acquisition Protocol. The impact of individual clinical and his-
topathological factors on the treatment outcome was evaluated by uni- and mul-
tivariate analysis.
 Results Combined therapy was performed in 142 patients, and 93 patients had radiother-
apy only. In each of the two subgroups, the performance status of patients was as-
sessed as “poor” in 7% and 30%; the proportion of T1–2 tumours was 53.6% and 
16.1%, and the proportion of cN0-stage tumours was 38% and 29%. The 5-year 
survival without local failure in surgically treated and irradiated only patients was 
89% and 30%, without neck failure 85.7% and 50.3%, without any failure 79.1% 
and 27.5%, and overall survival 43.9% and 11.5%, respectively (all P<0.0001). In 
multivariate analysis, the performance status and cT-stage emerged as independ-
ent prognostic factors for all four types of survival analyzed. The type of therapy 
retained its independent prognostic value only in the case of survival without lo-
cal failure.
 Conclusions The only independent predictors of survival were performance status and cT stage, 
whereas the type of therapy impacted only local cure rate. The difference in sur-
vival results between the two treatments reﬂ ects primarily selection bias which 
occurred when patients were directed to one of the two treatment options.
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BACKGROUND
The term cancer of the oral cavity (OC) denotes all 
types of malignancies occurring in the area ex-
tending from the vermilion border to the pos-
terior edge of the hard palate or to the mobile 
tongue. The majority of patients with oral cancer 
are elderly males with a history of smoking and 
alcohol abuse [1]. In Slovenia in 2003, 87 men 
and 19 women contracted cancer of the OC (ex-
cluding lip carcinoma) [2].
Histologically, the most frequent type of OC can-
cer is squamous cell carcinoma (SCC), covering 
almost 90% of all cancers in this area [1]. The 
risk for developing carcinoma of the OC is di-
rectly proportional to the degree and length of 
exposure of the oral mucosa to tobacco. Alcohol 
additionally intensiﬁ es local carcinogenic effect 
of the tobacco; hence, areas that are longer ex-
posed to alcohol will probably more frequently 
contract cancer. There are also other factors that 
inﬂ uence the development of cancer, e.g. genet-
ic susceptibility to mutagenicity of certain sub-
stances, deﬁ ciency of vitamin A in food and de-
vices that cause chronic mechanical irritation of 
the mucous membrane, such as a carelessly de-
signed dental prosthesis [1,3].
The most frequent site of SCC of the OC is the 
mobile tongue, usually its lateral edges, where 
35–40% of all cases occur. The next most fre-
quent site is the ﬂ oor of the mouth, with the oc-
currence of 30–35% of all cases, while other are-
as in the mouth are less frequently attacked [4]. 
Given that these cancer sites are easily accessible 
and that the morbidity is rather low, the majority 
of patients with early stage disease are operated 
on, whereas patients with advanced but still oper-
able carcinoma are treated with surgery in com-
bination with postoperative irradiation and some 
particular cases also with chemotherapy. Tumours 
which are technically inoperable are treated with 
radiotherapy (RT) and concomitant chemother-
apy [1].
AIM
The results of OC carcinoma treatment have 
not been systematically analyzed in Slovenia. 
Therefore, the aim of our study was to assess the 
results of treatment of SCC of the OC (exclud-
ing carcinoma of the lip) in patients treated with 
radical or postoperative RT at the Institute of 
Oncology Ljubljana (IOL) in the years between 
1990 and 1995.
MATERIALS AND METHODS
Selection of patients and data collection
Patients who were treated for SCC of the OC with 
curative percutaneous RT between the years 1990 
and 1995 at the IOL were included. Patients with 
synchronous or previously treated but uncured 
malignancy as well as patients with incomplete 
or missing medical documentation were exclud-
ed from the study.
Main data sources were the database of the 
Cancer Registry of the Republic of Slovenia and 
medical records archived at the IOL, Department 
of Otorhinolaryngology and Cervicofacial 
Surgery and Department of Maxillofacial and 
Oral Surgery, both at the University Medical 
Centre Ljubljana, and the Department of 
Otorhinolaryngology at the Maribor Teaching 
Hospital. The patients’ data were gathered from 
the medical records by following the uniform 
Data Acquisition Protocol, which consisted of 
the following data groups:
–  patients’ data: sex, age, performance status (due 
to incomplete descriptions, only a simpliﬁ ed 
two-grade scale was used, i.e. good, correspond-
ing to World Health Organization [WHO, Ref. 
5] grade ≤1 and poor, corresponding to WHO 
grade >1), haemoglobin concentrations before 
and after treatment;
–  data on the disease: anatomic sub-site of the 
primary tumour origin, disease stage accord-
ing to the International Union Against Cancer 
[UICC, Ref. 6] TNM staging system, differen-
tiation grade and keratinization;
–  irradiation parameters: time interval from di-
agnosis to the beginning of therapy, time in-
terval from surgery to irradiation (in postop-
eratively irradiated patients), daily irradiation 
dose, a total nominal tumour dose, frequency 
and duration of involuntary interruptions of ir-
radiation, intensity of RT (in terms of biolog-
ically effective dose [BED, as deﬁ ned in Ref. 
7]);
–  date and site of the ﬁ rst recurrence (in the 
case of persisting disease after the therapy or 
recurring disease in less than 4 months af-
ter the completed therapy, the date of com-
pleted therapy was deﬁ ned as the recurrence 
date);
–  date and cause of a patient’s death.
The follow-up of patients and recording of events 
were completed on June 16, 2003.
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Statistical analysis
Data were analyzed by using the statistical program 
package SPSS, version 8.0 (SPSS Inc, Chicago, 
Illinois, USA), according to the intention -to-treat 
principle. All statistical tests were two-sided and 
a P value of <0.05 was considered statistically sig-
niﬁ cant.
Continuous variables were deﬁ ned by arithmetic 
mean, range and standard deviation, and cate-
gorical variables by the rate of occurrence. T-test 
for comparing two independent samples was used 
for continuous variables, and chi-square test or 
Fisher’s exact test to evaluate the differences in 
frequency distribution of categorical variables. 
Univariate analysis of patients’ survival was carried 
out using the Kaplan-Meier product-limit meth-
od [8] and log-rank comparison to evaluate the 
difference between the survival curves [9]. The 
analysis involved (i) survival without local failure 
(event: recurrence of primary tumour), (ii) surviv-
al without neck failure (event: recurrence on the 
neck), (iii) survival without any failure (event: re-
currence on the primary site and/or in regional 
lymphatics, and/or distant metastases), and (iiii) 
overall survival (all deaths considered as events). 
The follow-up period and survival were calculated 
from the ﬁ rst day of therapy. Multivariate analysis 
was performed according to Cox’s proportional 
hazard model where only variables that proved 
to be statistically signiﬁ cant by univariate analy-
sis were introduced [10].
RESULTS
Descriptive Data
Having examined the medical ﬁ les, a list of 486 pa-
tients was created. Having taken into account the in-
clusion criteria, we could include only 235 patients 
in the ﬁ nal statistical analysis (Figure 1). Of these 
Included patients:
N=142
SRT
N=93
Radical RT
N=15
Surgery only
N=43
Paliative RT
N=293
Squamous cell carcinoma
N=11
Other histologies
N=101
Incomplete data
N=33
Synchronous/uncured
previous malignancy
N=48
Primary tumour origin
other than oral cavity
N=304
N=182
All patients
N=486
Figure 1. Selection of patients who entered the study (N – Number of patients; SRT – Surgery and postoperative radiotherapy; 
RT – Radiotherapy).
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235 patients, 142 (60.4%) were treated with surgery 
and postoperative RT (SRT group), and 93 (39.6%) 
were treated with curative RT alone (RT group). 
Mean age of all patients was 57.4 years (range 31–
92); the ratio between male and female patients was 
14.7/1. Characteristics of patients and tumours and 
comparison of the two groups are shown in Table 
1, and the differences between clinical and patho-
logical assessments of T-, N- and overall stage in the 
SRT group (stage migration) are shown in Table 
2. The most frequent sites of origin of the primary 
tumour were the ﬂ oor of the mouth (45.5%) and 
the tongue (38.3) (Table 3).
At diagnosis, metastases in the cervical nodes 
were more frequently detected in patients with 
Parameter Treatment modality P-value*
All (N=235) SRT (N=142) RT (N=93)
Age (years)** 57.4, 31-92 56.7, 31-82 58.6, 36-92 NS
Sex (M/F) 14.7/1 14.8/1 14.5/1 NS
Performance status
 – good  197 (83.3%)  132 (93.0%)  65 (69.9%) <0.0001
 – poor  38 (16.2%)  10 (7.0%)  28 (30.1%)
Hb (g/L)**
 – before RT 134.0, 69-190 127.9, 107–153 137.0, 69–190 NS
 – after RT 122.9, 67-153 122.4, 77–152 123.1, 67–153 NS
cT-stage
 – cT1  15 (6.4%)  13 (9.2%)  2 (2.1%) <0.0001
 – cT2  76 (32.3%)  63 (44.4%)  13 (14.0%)
(T1+T2 vs. T3+T4)
 – cT3  49 (20.9%)  28 (19.7%)  21 (22.6%)
 – cT4  95 (40.4%)  38 (26.8%)  57 (61.3%)
cN-stage
 – cN0  81 (34.5%)  54 (38.0%)  27 (29.0%) <0.0001
 – cN1  56 (23.8%)  34 (23.9%)  22 (23.7%) (N0 vs. N+)
 – cN2  90 (38.3%)  53 (37.3%)  37 (39.8%)
 – cN3  8 (3.4%)  1 (0.7%)  7 (7.5%)
Overall UICC TNM stage
 – SI  9 (3.8%)  7 (4.9%)  2 (2.2%) <0.001
 – SII  33 (14.0%)  28 (19.5%)  5 (5.4%)
(SI+SII vs. SIII+SIV)
 – SIII  56 (23.8%)  38 (26.8%)  18 (19.4%)
 – SIV  137 (58.3%)  69 (48.6%)  68 (73.1%)
Degree of diff erentiation
 – G1  38 (16.2%)  26 (18.3%)  12 (12.9%) NS
 – G2  133 (56.6%)  89 (62.7%)  44 (47.3%)
(G1+G2 vs. G3)
 – G3  30 (12.8%)  16 (11.3%)  14 (15.1%)
 – GX  34 (14.5%)  11 (7.7%)  23 (24.7%)
Table 1. Basic descriptive data on patients and tumours by treatment modality.
* Comparison between SRT and RT groups. ** Average value, range.
N – Number of patients; SRT – Surgery and postoperative radiotherapy; RT – Radiotherapy; Hb –Haemoglobin; NS – Nonsignifi cant 
(statistically) diff erence.
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locally advanced tumours (cT3–4, 72.9%) than 
in patients with early tumours (cT1–2, 53.8%; 
p=0.003). In the SRT group of patients in whom 
clinical examination at diagnosis detected no 
evidence of metastases in the regional lymph 
nodes (N=54), metastases were conﬁ rmed in 
24% of these cases by a histopathological exam-
ination of the resected specimen following sur-
gical treatment. Metastases were more frequent 
in patients with tongue carcinoma (35%) than 
in those with ﬂ oor of the mouth tumour (20%). 
In patients with clinically determined neck node 
involvement (N=88), histopathological exami-
nation of resected tissue from the neck did not 
show any metastases in altogether 43.2% of cas-
es (tongue carcinoma 44.4%; ﬂ oor of the mouth 
carcinoma 45.7%).
Course and technique of irradiation
The mean interval from the diagnosis (in RT 
group) or surgery (in SRT group) to the ﬁ rst 
day of RT was 23.7 days (range 0–186) and 27.9 
days (range 8–119), respectively. More than 95% 
of patients of both groups were irradiated by a 
telecobalt unit. Daily doses ranged between 1.8 
and 2.0Gy in 78.5% of patients from the RT group 
and in 96.5% of patients from the SRT group. In 
patients who were treated with radical RT, the 
applied tumour dose was more frequently lower 
by >4Gy from the initially planned tumour dose 
than in postoperatively irradiated patients (19.4% 
vs. 9.1%; p=0.040). In the RT group, the thera-
py was more frequently discontinued (55.9% vs. 
26.8%, p=0.0001) and the breaks were also long-
er (11.7 days vs. 2.6 days, p=0.0001) compared to 
the SRT group. In both groups, RT was prema-
turely completed in 23.7% of patients and 13.4% 
of patients, respectively (P>0.05).
Survival of patients
Mean follow-up of all patients (regardless of treat-
ment modality) was 42.8 months (range 2–157) 
and was 80.0 months (range 3–137) for those 
alive at the last follow-up examination.
All four types of survival in each of the two groups 
of patients are graphically presented in Figure 2. 
In all cases, the differences were statistically sig-
niﬁ cant (P<0.0001), speaking in favour of post-
operatively irradiated patients (Table 4). In the 
case of survival without local failure, the differ-
ence between the two groups of patients exceed-
ed the threshold of statistical signiﬁ cance in pa-
tients with early stage tumours (cT1+2; P=0.0217) 
as well as in those with locally advanced tumours 
(cT3+4; P<0.0001). Survival without neck failure 
was signiﬁ cantly different only in the N+ subgroup 
(p<0.0001), whereas in cases of survival without any 
failure and of overall survival, the difference was 
signiﬁ cant only in patients with advanced disease 
(UICC TNM stage III+IV; P<0.0001) (Table 4).
Parameter Clinicalassessment
Pathological 
assessment
T-stage
 – T1  13 (9.2%)  10 (7.0%)
 – T2  63 (44.4%)  67 (47.2%)
 – T3  28 (19.7%)  26 (18.3%)
 – T4  38 (26.8%)  39 (27.5%)
N-stage
 – N0  54 (38.0%)  79 (55.6%)
 – N1  34 (23.9%)  31 (21.8%)
 – N2  53 (37.3%)  32 (22.5%)
 – N3  1 (0.7%)  0 (0.0%)
Overall UICC TNM stage
 – SI  7 (4.9%)  4 (2.8%)
 – SII  28 (19.5%)  43 (30.3%)
 – SIII  38 (26.8%)  37 (26.1%)
 – SIV  69 (48.6%)  58 (40.8%)
Table 2. Distribution of clinical and pathological T-, N- and overall 
UICC TNM stages in SRT group (N=142).
Anatomic subsite
Treatment modality
All (N=235) SRT (N=142) RT (N=93)
Floor of mouth  107 (45.5%)  71 (50.0%)  36 (38.8%)
Tongue  90 (38.3%)  47 (33.1%)  43 (46.2%)
Lower gum  20 (8.5%)  13 (9.1%)  7 (7.5%)
Retromolar trigon  15 (6.4%)  9 (6.3%)  6 (6.4%)
Upper gum  1 (0.4%)  1 (0.7%)  0
Buccal mucosa  2 (0.8%)  1 (0.7%)  1 (1.1%)
Hard palate  0  0  0
Table 3. Anatomic subsite of primary tumour origin in oral 
cavity.
N – Number of patients; SRT – Surgery and postoperative 
radiotherapy; RT – Radiotherapy.
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Higher cure rate in the SRT group was observed in 
patients whose performance status was assessed as 
good than in those in poor general condition. At ﬁ ve 
years, survival without local and regional failure was 
83% vs. 64%, respectively (P=0.040), survival without 
any failure 81% vs. 53%, respectively (P=0.007), and 
overall survival 43% vs. 22%, respectively (P=0.031). 
In patients with no unfavourable histopathologi-
cal prognostic factors (e.g. extracapsular tumour 
spread, tumour emboli in the lymphatic or blood 
vessels, perineural tumour spread), 5-year survival 
without local and regional failure was 86%, whereas 
in patients with adverse prognosticators (single or 
in combination) it was 72% (P=0.018). Improved 
survival with local and regional failure was noted 
also in patients younger than 53 years compared 
to older ones (87% vs. 70%, P=0.038); differences 
in survival without any failure and overall survival 
were not statistically signiﬁ cant.
A more detailed univariate analysis of survival in 
the RT group indicated the vital role of the pa-
tient’s performance status and of therapy intensi-
ty. Patients who were in better general condition 
had longer survival than patients in poorer gener-
al condition; this was valid for all types of survival 
analyzed (P<0.05). Higher RT intensity, expressed 
in terms of BED, was a key factor, prognosticating a 
longer survival, but only in good performance status 
patients. At ﬁ ve years, survival without local and re-
gional failure of these patients was 60%, whereas in 
the group treated with less intensive therapy it was 
only 33% (P=0.024). The same was observed in the 
case of survival without any failure, but not in the 
case of overall survival (19% vs. 12%, P>0.05).
Treatment results of the second half of the obser-
vation period (1993–1995) were signiﬁ cantly su-
perior to those from the ﬁ rst period (1990–1993). 
Hence, survival without local and regional failure 
at ﬁ ve years in the SRT group was 77% in the ﬁ rst 
half-term of the observation period, and in the 
second, 87%. Accordingly, median survival with-
out local and regional failure in the RT group 
was also extended from 6 to 29 months.
The results of multivariate analysis are presented 
in Table 5. Performance status and cT-stage of the 
disease proved to be the key independent prog-
nostic factors. The poor performance status pa-
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Figure 2. Survival of patients by treatment modality (SRT – Surgery and postoperative; RT – Radiotherapy).
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tients and those with locally advanced disease of 
clinical stages T3–4 did worse with respect to all 
types of survival analyzed than patients in good 
general condition and with early stage (cT1–2) 
tumours. Mode of therapy reached the thresh-
old of statistical signiﬁ cance only in the case of 
survival without local failure.
DISCUSSION
The presented results give an insight into the efﬁ -
cacy of radical treatment for SCC of the OC per-
formed at the IOL in the period 1990–1995, pro-
vide an estimate of the prognostic signiﬁ cance of 
some patient-, tumour- and treatment-related fac-
tors and allow a comparison with the treatment 
results obtained at other institutions. However, 
the inherent drawbacks of the retrospective na-
ture of our study should be taken into account.
Patients’ characteristics
Demographic characteristics of our patients were 
similar to those from comparable studies performed 
elsewhere [11–13]. The only exceptions were a 
more pronounced difference between the sexes 
in our patient group with a male-to-female ratio of 
14.7/1 and an unusually high percentage (83.3%) 
of patients with the performance status deﬁ ned as 
good. The latter is mainly due to the selective crite-
ria applied in the recruitment of patients eligible 
for surgery: in the SRT group, the percentage of 
patients in good performance status was as high as 
93%, whereas in the RT group it was statistically sig-
niﬁ cantly lower, amounting to only 69.9%
Tumour characteristics
In view of the frequency distribution of primary 
tumour origin in the OC and distribution of cT-, 
cN- and overall UICC stages, our data are con-
sistent with the data from the literature [4,14]. 
Some digressions were observed in tumours of 
the cheek (only 2 cases were detected), and in 
tumours of the hard palate (not found in our 
patients). In the SRT group, the distribution of 
patients with cT1–2 and cT3–4 disease stages 
appeared to be fairly even (53.5% and 46.5%, 
Survival
Treatment modality
P-value**SRT (N=142) RT (N=93)
N Survival* N Survival*
Without local failure
 – cT1+T2 76 93.3% 15 70.5% 0.0217
 – cT3+T4 66 82.5% 78 22.5% <0.0001
 – all 142 89.0% 93 30.0% <0.0001
Without neck failure
 – cN0 54 91.2% 27 85.0% NS
 – cN+ 88 74.1% 66 22.6% <0.0001
 – all 142 85.7% 93 50.3% <0.0001
Without any failure
 – stage I–II 35 93.1% 7 85.7% NS
 – stage III–IV 107 74.1% 86 22.6% <0.0001
 – all 142 79.1% 93 27.5% <0.0001
Overall
 – stage I–II 35 59.9% 7 28.6% NS
 – stage III–IV 107 38.3% 86 10.1% <0.0001
 – all 142 43.9% 93 11.5% <0.0001
Table 4. Survival of patients after fi ve years of follow-up by treatment modality.
*At fi ve years of follow-up; ** Comparison between SRT and RT groups.
N – Number of patients; SRT – Surgery and postoperative radiotherapy; RT – Radiotherapy.
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respectively), while in the RT group the distri-
bution was less favourable, being biased toward 
advanced tumours (16.2% and 83.9%, respec-
tively). The comparison in the frame of overall 
UICC stages III and IV also showed that, in the 
SRT group, the incidence of cT4 tumours was 
lower (35%) than in the RT group (84%). These 
differences between the groups are statistically 
signiﬁ cant and are due to a selection bias – re-
ferring patients with prognostically less favoura-
ble disease to treatment with RT alone.
According to the data from the Cancer Registry of 
Slovenia, in the period 1983–1997, the percentage 
of patients with SCC of the OC without regional 
lymph node involvement was 29.5% [15], where-
as this percentage among the patients from our 
study was 34.5% (SRT 38%, RT 29%). In reports 
comparable to ours, the percentage of cN0 stage 
ranged from 23% to 89%, which reﬂ ects the dif-
ferences in the distributions of cT stages and of 
primary tumour origin in the OC between indi-
vidual studies (4, 16). The incidence rate of cN+ 
stage increased with cT stage and was statistically 
signiﬁ cantly higher in patients with cT3–4 tumours 
than in those with cT1–2 tumours (72.9% vs. 53.85, 
P=0.003). This difference was observed in both pa-
tients with carcinoma of the ﬂ oor of the mouth and 
patients with carcinoma of the tongue. Due to the 
small number of patients, the analysis of other an-
atomic subsites did not seem reasonable.
In 38% of patients from the SRT group who were 
without regional lymph node involvement (cN0) 
at diagnosis, metastases were diagnosed after sur-
gery. A similar share of patients with false nega-
tive cN0 stage was also reported by other authors, 
ranging between 15% and 40% [4,16]. On the 
other hand, the percentage of patients with false 
positive cN+ stage was as high as 43.2%.
Treatment results
From the evidence it may be concluded that RT 
has a curative potential in early stage (T1–2) tu-
mours comparable to surgery. Treatment results 
with irradiation in more advanced stages (T3–4) 
are less favourable. Local control of T1–T2 tu-
mours at ﬁ ve years after RT ranges between 43% 
and 98%, whereas in patients with locally advanced 
disease it is only 17–54%. Corresponding overall 
survival rates at ﬁ ve years are 36–85% and 5–39%, 
respectively [12,13,17–24]. In the advanced stag-
es of the disease, the combination of surgery and 
postoperative irradiation yields better local and 
regional control of the disease and better survival 
of patients [11,13,19,21]. So far, no randomized 
studies have been performed to compare com-
bined treatment with RT alone. This may only be 
proved indirectly, by retrospective studies such 
as ours which are subject to all the drawbacks of 
such analyses, including the selection bias which 
seems to be the most critical of all.
In the studied period, the results of combined 
treatment of our patients were similar to the treat-
ment results obtained elsewhere. Moreover, the 
pattern and time frame of disease recurrence 
Parameter
Survival
Without local failure Without neck failure Without any failure Overall
P-value HR P-value HR P-value HR P-value HR
Treatment modality
 – SRT
 – RT <0.0001 0.15 NS – NS – NS –
Performance status
 – good
 – poor 0.0236 0.53 0.0006 0.31 <0.0001 0.32 <0.0001 0.41
cT-stage
 – cT1–2 
 – cT3–4 0.0346 0.37 0.057 0.283 0.0001 0.23 0.0001 0.44
Table 5. Multivariate analysis of survival.
SRT – Surgery and postoperative radiotherapy; RT – Radiotherapy; HR – Hazard ratio; NS – Nonsignifi cant (statistically) diff erence.
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were also comparable to the literature data, 
whereas the results of treatment with radical RT 
were worse than those reported from other in-
stitutions [12,13,16–19]. However, in both cases 
the treatment results in the period 1993–1995 
were statistically signiﬁ cantly better than in the 
period 1990–1992.
The reasons for the worse outcome in the RT 
group may lie in the recruitment of patients for 
RT and its characteristics:
1. The distribution of cT stages in the RT group 
was biased toward advanced tumour stages 
(T1–2 tumours 16.1%, T3–4 tumours 83.9%), 
whereas the distribution in the SRT group and 
in comparable studies performed by other in-
stitutions [12,13,17–20] was more favourable. 
In the multivariate analysis of survival, the cT 
stage of the disease, besides the performance 
status, proved to be the next most important 
prognostic factor.
2. In the majority of comprehensive retrospec-
tive studies, at least part of the irradiation in 
patients with smaller tumours was delivered 
using brachytherapy, which deﬁ nitely can im-
prove the results [17,18,29]. All the patients in 
our study were treated exclusively with percu-
taneous irradiation.
3. In as many as 17% of patients, surgery was con-
traindicated due to poor medical condition, and 
another 17% of patients refused the proposed 
operation (possibility of lower motivation for 
therapy cannot be ruled out). Therefore, the 
performance status of patients in the RT group 
was assessed as poor in as many as 30% of cas-
es (in the SRT group 7%, P<0.0001). This re-
sulted in frequent interruptions (55.9%) of RT 
of long duration (mean 11.7 days), and in the 
applied tumour dose, which was >4 Gy lower 
than the prescribed tumour dose in one ﬁ fth 
(19.4%) of patients from the RT group.
4. It is well recognized that treatment intensity de-
pends on the performance status of a patient: 
those in poor general condition are not ﬁ t to 
tolerate aggressive RT schedules. Given the high 
percentage of such patients, it was expected that 
the treatment results in the RT group would be 
less favourable. On the other hand, in a select-
ed group of irradiated patients with good per-
formance status it was proved that more inten-
sive treatment (i.e. higher BED) prognosticated 
longer survival without local, regional or any 
failure. The survival of these patients was by all 
means comparable to the survival of patients 
from other comparable studies [11–13,17–19]. 
Treatment intensity, however, did not affect 
overall survival because of competitive (non-
malignant) risks of death.
The results of univariate and multivariate analy-
ses of the prognostic value of individual clinical 
and histopathological factors are congruent with 
the published results [11–13,17–21]. The per-
formance status of patients and cT stage of dis-
ease proved to be two major independent prog-
nosticators. Irrespective of the applied treatment 
modality, the performance status has kept its in-
dependent prognostic value for all types of sur-
vival analyzed. The same holds true also for cT 
stage. As expected, after correcting the inﬂ uence 
of performance status and primary tumour stage, 
treatment modality became of lesser importance. 
Combined treatment with surgery and postoper-
ative RT was found to be a statistically signiﬁ cant 
and independent prognosticator only for survival 
without local failure, whereas in all other analyzed 
survival types no statistically signiﬁ cant differenc-
es were observed between the two treatment mo-
dalities. It may therefore be assumed that, for re-
gional control of the disease, irradiation alone 
may be as effective as the combination of surgery 
and postoperative RT, provided that both groups 
of patients are comparable in performance status 
of patients and cT stage of disease. Furthermore, 
the length of overall survival is far more depend-
ent on the lifestyle of patients and their habits 
than on the treatment modality.
CONCLUSIONS
There are several possibilities to compensate the 
negative inﬂ uence of adverse prognosticators and 
to improve the rather poor presented results in 
the radical RT group, both obviously originating 
from the selection bias when referring patients to 
different treatment programmes (i.e. patients with 
less advanced tumours and/or better performance 
status are usually directed to surgery). The most 
reliable seems to be to upgrade the therapeutic 
regimes with additional chemotherapy or brachy-
therapy and to improve RT planning and delivery 
by means of intensity-modulated RT (IMRT). The 
foreign experience is favourable in all three cas-
es. In this context, the most interesting would be 
a comparison of results obtained so far with the 
treatment results obtained in the next ﬁ ve-year 
period, which was marked speciﬁ cally by the in-
troduction of chemotherapy into the majority of 
RT regimes, i.e. postoperative RT as well as radical 
RT of inoperable tumours [22–24]. Unfortunately, 
the treatment results of brachytherapy and IMRT 
are not yet available at the IOL because of insufﬁ -
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cient technical capacities that do not allow their 
application in routine clinical practice.
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